Skip to content
DataLookout
Menu

INFINITYNCT06694740

Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 20 words
    • Trial sites expanded: 2 → 6 locations
    • Secondary endpoints: details revised at 1 of 9 entries
  2. Notable Primary completion pushed from Feb 2028 to Mar 2029
    • Start date: Jan 12, 2026 to Feb 24, 2026
    • Study completion pushed from Apr 2028 to May 2029
    v5
  3. Minor Secondary endpoints revised (9)v4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Jan 2026 to Jan 12, 2026
    v3
  5. Notable Start date: Jan 2025 to Jan 2026v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

number of days alive without mechanical ventilation
Timeframe: on Day 28 after drug administration

Secondary (9)

Evaluate the efficacy of IFNy in correcting PAIS-defining biological abnormalities (re-ascension of mHLA-DR above 8,000 AB/C) between patients treated with recombinant interferon gamma 1-b versus placebo
Evaluate, depending on the randomization arm, the kinetics of plasma inflammatory parameters between patients treated with recombinant interferon gamma 1-b versus placebo
mortality at Day 28 and Day 90 after randomization
incidence of nosocomial infections during intensive care unit stay
number of days alive whithout antibiotic
Show 4 moreShow less
length of stay in intensive care between patients
- Compare organ failure score (SOFA) kinetics between patients treated with recombinant interferon gamma 1-b versus placebo
Evaluate, depending on the randomization arm, the transcriptomic profile of circulating peripheral blood mononuclear cells count between patients treated with recombinant interferon gamma 1-b versus placebo
Evaluate, depending on the randomization arm the leucocyte count between patients treated with recombinant interferon gamma 1-b versus placebo

Arms and interventions

interferon gamma-1b injectionExperimental

Patients randomized to the experimental arm will receive : Recombinant human interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

Placebo injectionPlacebo comparator

Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)

Drugs: Interferon Gamma 1-b, Placebo

Sites

6 sites in 1 country